Always up to date

Groundbreaking research into nuclear medicine? The contribution of nuclear energy to climate goals? We make a concrete contribution to a cleaner, healthier world.

Follow the current developments regarding our nuclear research, our advice, and the production of life-saving nuclear medicines here.

Want to stay informed of all nuclear developments regarding health and energy? Sign up for our updates at the bottom of this page.

Contact for the media

Spokesperson coordinates all incoming media inquiries. If you have a question, please contact:

Cora Blankendaal
Press officer

Latest news

26 November 2021

Effective 1 February 2022, Peter Dijk has accepted the position of programme director PALLAS

18 November 2019

Radiopharmaceuticals are vitally important. That’s why NRG|PALLAS, together with partners like AVL, are working on the development of new radiopharmaceuticals in our FIELD-LAB. With this development, we are reinforcing NRG|PALLAS’ leading position in the field of medical isotopes worldwide. We’ve now succeeded in developing a new, efficient and high quality production process for lutetium-177. In order to meet the increasing demand for this kind of radiopharmaceuticals in the future, we will embark on the construction of an isotope production facility (the Nuclear Health Center) next year, followed by the construction of the PALLAS reactor to replace the High Flux Reactor in Petten.

09 October 2019

Ultra Safe Nuclear Corporation (USNC) announces that it has begun working with the Nuclear Research & Consultancy Group (NRG) from the Netherlands. NRG will implement a program to analyze performance and safety attributes of the company’s proprietary Fully Ceramic Microencapsulated (FCMTM) fuel designed for use in its Micro Modular ReactorTM (MMRTM).

PETTEN - Soon there will be new treatments for metastatic prostate cancer available, based on the drug PSMA linked to the radioisotope Lu-177. As prostate is a common disease, the use of this isotope will increase spectacularly.

18 March 2021

The High Flux Reactor in Petten, from now on, produces only medical isotopes with low-enriched uranium. Until recently, the productions for NRG’s Belgian partner IRE were still based on high-enriched uranium, because IRE could not fully process low-enriched uranium. But now IRE has, partially, converted its chemical process to low-enriched uranium. This means that NRG can take the final step and end using high-enriched uranium in the HFR.

14 January 2021

The Foundation NRG and the Foundation Preparation Pallas-reactor (PALLAS) intend to fuse together as one organisation, as announced by Bertholt Leeftink, CEO NRG/PALLAS, today during the New Year’s Toast. This spring, the proposal for the new organisation will be further detailed. “By combining our forces, we are able to make large steps forward in the development and production of nuclear medicines used for diagnostic purposes and for the treatment of patients suffering from life-threatening diseases. To this end, we need to establish a state-of-the art infrastructure that is being developed as we speak,” said Bertholt Leeftink.

17 November 2020

NRG has kicked-off the Nuclear Innovation Conference discussions online with a round table discussion and testimonials from some of the parties supporting the NIC.

12 November 2020

Terrestrial Energy and Nuclear Research and Consultancy Group (NRG) have started a graphite irradiation testing program at NRG’s Petten Research Centre’s High Flux Reactor (HFR) in the Netherlands.

15 June 2020

Last month, the reactor in Petten had a record production and was therefore able to continue to provide 30,000 patients daily with medical isotopes. The Corona crisis has caused complications for transport and logistics and due to this the European manufacturers are now turning to NRG.

28 May 2020

Amended governance The NRG Foundation (previously: Foundation ECN) and the Foundation Preparation Pallas-reactor (PALLAS) have made an important step forward. The executive board members and the supervisory board members of both organizations will sit on the boards of both companies, via a so-called “personele unie” (a situation in which both organizations continue to exist autonomously, even if the same executive and supervisory boards govern them).

06 July 2020

The Coronavirus has a worldwide impact. The outbreak of this and the accompanying government measures lead to a situation that we have never experienced before. NRG follows developments closely and adopts the national measures that the Dutch government prescribes.

06 January 2020

The old chemical laboratory and the old materials science laboratory, of both approx. 65 x 50 metres, have been remediated and emptied radiologically, chemically and asbestos in recent months. In addition to the old laboratories, the south-facing 40-metre-high chimney is also disappearing.

06 July 2020

Molten salt

NRG started a new experiment within their Molten Salt Technology Program. The experiment aims to simulate what happens when the molten salt cools down to below 150 oC.

15 October 2019

Nuclear Research & Consultancy Group (NRG) and McMaster University’s Nuclear Reactor (MNR) have teamed up to advance customer service to a new level

09 October 2019

Terrestrial Energy and NRG have established a graphite irradiation program that systematically analyzes IMSR graphite behavior as part of Terrestrial Energy’s comprehensive test program supporting the design of Integral Molten Salt Reactor (IMSR) and is being conducted at NRG’s facilities in the Netherlands.

17 September 2019

Molten salt

At the end of this summer we reached a historic milestone by successfully concluding an irradiation test on molten nuclear fuel salts inside the High Flux Reactor in Petten. This is the first irradiation of its kind since the research carried out in the USA in the 1960s.